AI Article Synopsis
- A study was conducted to assess the effectiveness of a modified photodynamic therapy (PDT) for patients with exudative age-related macular degeneration, which is typically hard to treat.
- The modified PDT, referred to as "Ironing PDT," involved using a moving laser spot to treat larger or more challenging lesions over a duration of 83 seconds.
- Results showed that 62.5% of patients had no exudation after 36 months, and while overall visual acuity didn't significantly change, some patients experienced improvement or maintained their sight after treatment.
Article Abstract
Background: To evaluate the effect of photodynamic therapy (PDT) using a modified procedure on exudative age-related macular degeneration having been conventionally difficult to treat.
Methods: The medical records of eight consecutive patients (eight eyes) with age-related macular degeneration treated with modified PDT were reviewed retrospectively. Modified PDT was used for the lesions that could not be covered by conventional use of PDT, either because the lesion was too large or too close to the optic disc. A moving PDT laser spot at constant speed, for 83 seconds, was used to cover the entire lesion, and was named "Ironing PDT." This retrospective study was performed with informed patient consent. It was approved by the Institutional Review Board of Kansai Medical University.
Results: No exudation could be found 36 months after treatment in five eyes (62.5%). There was no significant difference between the best-corrected visual acuity before PDT (0.95 logMAR) and after PDT (1.09 logMAR). The logMAR best-corrected visual acuity was improved in one eye, maintained in five eyes, and deteriorated in two eyes.
Conclusion: Ironing PDT decreased subfoveal fluid and preserved visual acuity in some patients with age-related macular degeneration difficult to treat with conventional therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795568 | PMC |
| http://dx.doi.org/10.2147/OPTH.S102171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Frailty and the risk of age-related macular degeneration: a prospective cohort and Mendelian randomization study.
J Gerontol A Biol Sci Med Sci
December 2024
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China; National Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai 200080, China.
Background: Both frailty and age-related macular degeneration (AMD) are related to aging and may share some common mechanisms. We aimed to examine the observational and causal association between frailty and the risk of age-related macular degeneration (AMD).
Methods: We included 320,810 participants free of AMD at baseline from the UK Biobank.
Productive infection of the retinal pigment epithelium by SARS-CoV-2: Initial effects and consideration of long-term consequences.
PNAS Nexus
December 2024
Department of Ophthalmology and Stein Eye Institute, University of California, Los Angeles, CA 90095, USA.
As the SARS-CoV-2 coronavirus continues to evolve and infect the global population, many individuals are likely to suffer from post-acute sequelae of SARS-CoV-2 infection (PASC). Manifestations of PASC include vision symptoms, but little is known about the ability of SARS-CoV-2 to infect and impact the retinal cells. Here, we demonstrate that SARS-CoV-2 can infect and perturb the retinal pigment epithelium (RPE) in vivo, after intranasal inoculation of a transgenic mouse model of SARS-CoV-2 infection, and in cell culture.
View Article and Find Full Text PDFPhotobiomodulation Therapy for Non-exudative Age-related Macular Degeneration.
Int Ophthalmol Clin
January 2025
Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas.
Age-related macular degeneration (AMD) is a chronic condition that causes gradual central vision loss, most commonly in patients 50 years or older. This disease is commonly classified as either dry (non-exudative) or wet (exudative). Most patients with AMD have the non-exudative form, characterized by the presence of drusen in the macula.
View Article and Find Full Text PDFUse of Home Optical Coherence Tomography for Retinal Diseases.
Int Ophthalmol Clin
January 2025
Cullen Eye Institute, Baylor College of Medicine, Houston, TX.
Modern treatment protocols for retinal diseases involve frequent in-office monitoring with optical coherence tomography (OCT) and treatment with anti-vascular endothelial growth factor injections. Monthly injections may yield the greatest visual outcomes but are the most burdensome for patients and physicians, while as-needed injections may lead to undertreatment. Hybrid protocols, such as treat-and-extend (TREX) have been conceived to bridge this gap.
View Article and Find Full Text PDFTyrosine Kinase Inhibitors: The Next Chapter in Reducing Treatment Burden for Exudative Retinal Diseases?
Int Ophthalmol Clin
January 2025
Retina Health Institute, Algonquin, IL.
Tyrosine kinase inhibitors (TKIs) serve to inhibit the phosphorylation cascade that usually leads to abnormal processes such as vascular leakage and tumorigenesis. Within retinal diseases specifically, dysregulation of the vascular endothelial growth factor receptor tyrosine kinases can lead to age-related macular degeneration and diabetic macular edema. These diseases have a growing prevalence and are leading causes of vision loss.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!